#India #Mumbai #ophthalmology #Lupin Limited #VISUfarma

Lupin Completes Acquisition of VISUfarma

In a strategic move to enhance its capabilities in the field of ophthalmology, Lupin Limited has announced the completion of its acquisition of VISUfarma B.V., a prominent European pharmaceutical company specializing in eye care. This acquisition is significant in reinforcing Lupin’s position within specialized healthcare and expanding its footprint across Europe, thus setting a strong foundation for further growth in the ophthalmic sector.

The acquisition, finalized on April 2, 2026, represents a transformative step for Lupin. With the integration of VISUfarma, Lupin is set to broaden its ophthalmology business, leveraging an extensive portfolio comprising over 60 well-established products. These products span vital areas such as dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialized nutraceuticals.

VISUfarma has a distinguished reputation in key European markets including Italy, the United Kingdom, Spain, Germany, and France. It boasts a highly skilled commercial team with in-depth knowledge of ophthalmology, established relationships in the industry, and a strong understanding of local market conditions. This expertise will be instrumental as Lupin addresses the growing global demand for innovative eye care solutions, particularly amidst challenges posed by an aging population and the increasing prevalence of diabetes-related ocular complications.

Vinita Gupta, the CEO of Lupin, emphasized the importance of this acquisition by stating, “This is a significant milestone for Lupin as we incorporate a differentiated portfolio of innovative eye health products, supported by a robust commercial infrastructure. Not only is this acquisition immediately accretive, but it also strategically expands our presence in Europe and accelerates the development of our specialty business.”

Furthermore, Paolo Cioccetti, CEO of VISUfarma, expressed enthusiasm about the new chapter with Lupin, pointing out, “We are thrilled to embark on this journey alongside Lupin. Their global reach, long-term vision, and commitment to ophthalmology make them the ideal partner for advancing the next stage of VISUfarma’s growth. Together, we aim to significantly impact the field of eye care in Europe and beyond.”

Background of Lupin and VISUfarma

Lupin Limited is recognized as a leading global pharmaceutical company based in Mumbai, India. The company serves over 100 markets, manufacturing both brand and generic pharmaceuticals, complex generics, biotechnology products, and active pharmaceutical ingredients. Renowned for its efforts in various therapeutic areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health, Lupin prides itself on delivering quality healthcare solutions worldwide. With 15 state-of-the-art manufacturing facilities and seven research centers globally, it employs over 24,000 dedicated professionals focused on improving patient health through its various subsidiaries.

VISUfarma, founded in 2016 through the merger of the Italian company Visufarma SpA and Nicox SA’s European operations, has established itself as a specialized ophthalmic pharmaceutical company. In 2025, VISUfarma reported revenues of €53 million across key markets including Italy, the United Kingdom, Spain, Germany, and France. VISUfarma was previously acquired by GHO Capital in 2016 and has been a pioneer in providing essential eye care solutions across Europe.

This acquisition not only enhances Lupin's product offerings but also strengthens its global market position, providing a more comprehensive and innovative range of solutions in ophthalmology for healthcare providers and patients alike. As the company looks to future developments, this milestone marks a new era of growth and opportunity, fostering deeper advancements in eye health care across the continent.

To learn more about Lupin Limited, visit lupin.com or follow the company on LinkedIn.